ClinChoice, a Philadelphia, PA- and Shangai, China-based clinical CRO company, raised $150M in Series E funding.
The round wasted by Legend Capital, with participation from Taikang Life Insurance, Sherpa Healthcare Partners, Lilly Asia Ventures and Apricot Capital.
The company intends to use the funds to fund its continued business expansion and innovative service offering worldwide.
Led by CEO Mr. Ling ZHEN, ClinChoice provides a clinical CRO that integrates One-stop Service Offerings for new bio-pharmaceutical and medical device clients worldwide. Their Service Offerings cover Clinical Operation, Project Management, Biostatistics, Data Management, Biostatistical Programming, Regulatory Affairs, Medical Affairs, Feasibility Research, HGRAC Submission, Clinical Safety Management, Site Management Organization, Nature Medicine/Traditional Chinese Medicine and Phase I Clinical Research. The company has over 3000 employees worldwide covering most of drug development hotbeds in US, China, multiple countries in Europe and Southeast Asia. With over 25 years of high-quality services, ClinChoice has completed more than 1,000 Phase I-IV full-service clinical projects and supported over 100 innovative drug registrations, clinical design and development.
FinSMEs
07/07/2022